- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04461171
Enhanced Recovery After Surgery in Extremity Sarcoma
July 13, 2023 updated by: Joshua Lawrenz
The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Specifically, the focus of this study will be regarding the administration of a perioperative non-narcotic, multimodal pain management pathway.
Primary endpoints collected with be short-term patient reported outcomes (pain scores [PROMIS] and [QoR-15]), limb function scores [MSTS], and key clinical outcomes (hospital length of stay, opioid requirements/prescribing data and perioperative complications).
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Vanderbilt-Ingram Service for Timely Access
- Phone Number: 800-811-8480
- Email: cip@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University Medical Center
-
Principal Investigator:
- Joshua M Lawrenz, MD
-
Contact:
- Vanderbilt-Ingram Service for Timely Access
- Phone Number: 800-811-8480
- Email: cip@vumc.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Any patient at Vanderbilt University Medical Center treated with surgical excision of a suspected extremity sarcoma
- Adult patients >17 years of age
- Patients of all preoperative opioid status (naïve or dependent)
Exclusion Criteria:
- Patients treated non-operatively
- Non-English speaking patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ERAS
Administration of a perioperative non-narcotic, multimodal pain management pathway.
|
Undergo an enhanced recovery after surgery program
|
No Intervention: Non-ERAS (Conventional)
Administration of a conventional perioperative pain management pathway that consists of both narcotic and non-narcotic pain medications.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain scores
Time Frame: 3 months
|
Measured by Quality of Recovery questionnaire (QoR-15) scale = 0-10 (0=none of the time and 10 = all of the time)
|
3 months
|
Pain scores
Time Frame: 3 months
|
Measured by Patient-Reported Outcomes Measurement Information System (PROMIS-29 Profile v2.0) Score 1-5 (1 being worst and 5 being best)
|
3 months
|
Limb function
Time Frame: 3 months
|
Measured by Musculoskeletal Tumor Society scoring system (MSTS) scored from 0-5 (5 being best and 0 being worst)
|
3 months
|
Clinical outcomes - length of hospital stay
Time Frame: 3 months
|
Measured by the number of days in the hospital
|
3 months
|
Clinical outcomes - opioid requirements
Time Frame: 3 months
|
Measured by the amount of opioids consumed
|
3 months
|
Clinical outcomes - perioperative complications (e.g. wound complications and 30-day readmission)
Time Frame: 3 months
|
Measured by the number of perioperative complications reported
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joshua Lawrenz, MD, Vanderbilt Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 14, 2020
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
June 10, 2020
First Submitted That Met QC Criteria
July 1, 2020
First Posted (Actual)
July 8, 2020
Study Record Updates
Last Update Posted (Actual)
July 17, 2023
Last Update Submitted That Met QC Criteria
July 13, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VICC SAR 2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
Clinical Trials on Enhanced Recovery After Surgery
-
Instituto Brasileiro de Controle do CancerWithdrawnEnhanced Recovery After Surgery | Gynecologic Surgical ProceduresBrazil
-
The Second Hospital of Shandong UniversityRecruitingLung Cancer | Surgery | ERASChina
-
Instituto Brasileiro de Controle do CancerRecruitingGynecologic Cancer | Enhanced Recovery After SurgeryBrazil
-
Chonnam National University HospitalCompleted
-
Services Hospital, LahoreCompletedEnhanced Recovery After SurgeryPakistan
-
University of Colorado, DenverRecruitingEnhanced Recovery After Surgery | Gynecologic DiseaseUnited States
-
University Hospital, GrenobleCompleted
-
Institut Paoli-CalmettesUnknown
-
University Hospital, Clermont-FerrandMinistry of Health, France; Direction Générale de l'Offre de SoinsUnknown
-
Grupo Español de Rehabilitación MultimodalInstituto de Salud Carlos III; Instituto de Investigación Sanitaria AragónRecruitingMajor SurgerySpain